Oral JAK inhibitor baricitinib effective in JIA

被引：0
|
作者：
McHugh, Jessica
机构：
[1] Nature Reviews Rheumatology,
来源：
NATURE REVIEWS RHEUMATOLOGY | 2023年 / 19卷 / 09期
关键词：
D O I：
10.1038/s41584-023-01019-y
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In a phase III trial, the oral Janus kinase inhibitor baricitinib was safe and effective in patients with juvenile idiopathic arthritis who previously had an inadequate response to DMARD therapy.
引用
收藏
页码：539 / 539
页数：1
相关论文
共 50 条
  • [41] BARICITINIB, AN ORAL JANUS KINASE (JAK) 1/JAK2 INHIBITOR, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ( RA) AND AN INADEQUATE RESPONSE TO TNF INHIBITORS: RESULTS OF THE PHASE 3 RA-BEACON STUDY
    Genovese, M. C.
    Kremer, J.
    Zamani, O.
    Ludivico, C.
    Krogulec, M.
    Xie, L.
    Beattie, S.
    Koch, A. E.
    Cardillo, T.
    Rooney, T.
    Macias, W.
    Schlichting, D.
    Smolen, J. S.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 75 - 76
  • [42] Characterising lymphocytes in newly diagnosed type 1 diabetes patients during and after treatment with the JAK inhibitor baricitinib
    Villanueva, L. Sanz
    Trivedi, P.
    Litwak, S.
    Catterall, T.
    Lai, S.
    Waibel, M.
    Krishnamurthy, B.
    Thomas, H.
    Kay, T.
    DIABETOLOGIA, 2024, 67 : S216 - S217
  • [43] Epigenetic modulation with oral histone deacetylase (HDAC) inhibitor as a new treatment option in JIA
    J Vojinovic
    A Furlan
    N Damjanov
    C D’Urzo
    CA Dinarello
    Pediatric Rheumatology, 9 (Suppl 1)
  • [44] Repigmentation of vitiligo with oral baricitinib
    Mumford, Blake P.
    Gibson, Andrew
    Chong, Alvin H.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2020, 61 (04) : 374 - 376
  • [45] Effective JAK inhibitor therapy in rheumatoid arthritis: can methotrexate be discontinued?
    Dougados, Maxime
    LANCET RHEUMATOLOGY, 2019, 1 (01): : E4 - E5
  • [46] Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
    Cutolo, Maurizio
    Meroni, Marianna
    JOURNAL OF INFLAMMATION RESEARCH, 2013, 6 : 129 - 136
  • [47] Identifying features of lymphocytes in newly diagnosed type 1 diabetes BANDIT participants after treatment with the JAK inhibitor baricitinib
    Villanueva, L. Sanz
    Trivedi, P.
    Litwak, S.
    Catterall, T.
    Waibel, M.
    Krishnamurthy, B.
    Thomas, H. E.
    Kay, T. W.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S347 - S347
  • [48] The JAK inhibitor baricitinib inhibits oncostatin M induction of proinflammatory mediators in ex-vivo synovial derived cells
    Weston, S.
    Macdonald, J. L.
    Williams, L. M.
    Roussou, E.
    Kang, N. V.
    Kiriakidis, S.
    Taylor, P. C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2022, 40 (09) : 1620 - 1628
  • [49] BARICITINIB EFFECTIVENESS AFTER A PREVIOUS INADEQUATE RESPONSE TO AN ALTERNATIVE JAK INHIBITOR: RESULTS FROM THE SWISS RHEUMATOID ARTHRITIS REGISTER
    Gilbert, Benoi T. T. P.
    Courvoisier, Delphine S.
    Mongin, Denis
    Lauper, Kim
    Guimaraes, Vanessa A.
    Mueller, Ruediger B.
    Finckh, Axel
    RHEUMATOLOGY, 2022, 61
  • [50] The JAK 1/2 inhibitor baricitinib prevents and reverses alopecia areata in C3H/HeJ mice
    Dai, Z.
    Xing, L.
    Jabbari, A.
    Christiano, A.
    Clynes, R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2014, 134 : S23 - S23
12345